title: The role of allogeneic stem cell transplantation in Hodgkin's lymphoma.
abstract: The treatment of patients with classical Hodgkin's lymphoma relapsing after autologous stem cell transplantation represents a clear unmet need. Overall long-term outcome is not the same in these patients and therapeutic options in this setting are very heterogeneous and include salvage CT and/or RT followed or not by a second stem cell transplantation, palliative care, new drugs, or biological agents. Despite the absence of prospective, randomized, clinical trials, allogeneic stem cell transplantation either from a HLA identical sibling or a matched, unrelated donor represents an attractive option for those young patients with chemosensitive disease after being treated with a salvage protocol. The use of reduced intensity conditioning regimens has been able to drastically decrease nonrelapse mortality, although relapse rate remains a significant issue in this setting. More intense conditioning protocols could eventually decrease the relapse rate after the allogeneic procedure and, as indicated by a recent retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation, nonrelapse mortality does not represent a major problem nowadays for patients with multiply relapsed Hodgkin's lymphoma. Brentuximab vedotin is an antibody-drug conjugate that selectively delivers monomethyl auristatin E, an antimicrotubule agent, into CD30-expressing cells. Its use has been approved recently for patients with Hodgkin's lymphoma relapsing after autologous stem cell transplantation. As a single dose, brentuximab vedotin is able to achieve an objective response rate of 75 % with 34 % of the patients achieving a complete remission. Its widespread use will most certainly change the treatment paradigm of this subgroup of patients, either avoiding the allogeneic procedure in some patients or by increasing the group of potential candidates to an allogeneic transplant being used as a "bridge to allo." Additional information on long-term outcome of patients being treated with this drug or the development of prospective clinical trials in this setting will most probably give some light to this question we have nowadays.
authors.affiliation: Hematology Department, Institut Català d'Oncologia - Hospital Duran I Reynals, Avda. Gran Via, 199 - 203, L'Hospitalet de Llobregat, 08908, Barcelona, Spain, asureda@iconcologia.net.
authors.forename: Anna
authors.initials: A
authors.lastname: Sureda
authors.forename: E
authors.initials: E
authors.lastname: Domenech
authors.forename: N
authors.initials: N
authors.lastname: Schmitz
authors.forename: P
authors.initials: P
authors.lastname: Dreger
mesh_terms: D000328:Adult; D000367:Age Factors; D000079963:Brentuximab Vedotin; D020350:Graft vs Tumor Effect; D006680:HLA Antigens / Q000737:chemistry; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage; D008870:Microtubules / Q000737:chemistry; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage; D012008:Recurrence; D012074:Remission Induction; D012307:Risk Factors; D033581:Stem Cell Transplantation / Q000379:methods*; D014019:Tissue Donors; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous / Q000379:methods*; D016896:Treatment Outcome
chemical_list: D006680:HLA Antigens; D018796:Immunoconjugates; D009842:Oligopeptides; D000079963:Brentuximab Vedotin; C495575:monomethyl auristatin E
references.citation: Lancet. 1993 Apr 24;341(8852):1051-4
references.pmid: 8096958
references.citation: Haematologica. 2009 Feb;94(2):230-8
references.pmid: 19066328
references.citation: Bone Marrow Transplant. 2010 Feb;45(2):219-34
references.pmid: 19584824
references.citation: N Engl J Med. 1979 May 10;300(19):1068-73
references.pmid: 34792
references.citation: Ann Oncol. 2013 Sep;24(9):2430-4
references.pmid: 23712545
references.citation: Haematologica. 2012 Feb;97(2):310-7
references.pmid: 21993674
references.citation: N Engl J Med. 2003 Jun 12;348(24):2386-95
references.pmid: 12802024
references.citation: Lancet. 2002 Jun 15;359(9323):2065-71
references.pmid: 12086759
references.citation: N Engl J Med. 1981 Jun 18;304(25):1529-33
references.pmid: 7015133
references.citation: Blood. 2009 Sep 3;114(10):2060-7
references.pmid: 19498021
references.citation: Biol Blood Marrow Transplant. 2006 Feb;12(2):172-83
references.pmid: 16443515
references.citation: Leukemia. 2013 Jun;27(6):1419-22
references.pmid: 23135356
references.citation: Bone Marrow Transplant. 2014 Feb;49(2):190-4
references.pmid: 24185585
references.citation: Lancet. 2005 Jun 4-10;365(9475):1934-41
references.pmid: 15936420
references.citation: J Clin Oncol. 2002 Feb 1;20(3):630-7
references.pmid: 11821442
references.citation: J Clin Oncol. 2008 Jan 20;26(3):455-62
references.pmid: 18086796
references.citation: J Clin Oncol. 1996 Apr;14(4):1291-6
references.pmid: 8648386
references.citation: Blood. 2010 May 6;115(18):3671-7
references.pmid: 20220116
references.citation: J Clin Oncol. 1996 Feb;14(2):572-8
references.pmid: 8636773
references.citation: Bone Marrow Transplant. 2005 May;35(10):943-51
references.pmid: 15806128
references.citation: J Clin Oncol. 2011 Mar 10;29(8):971-8
references.pmid: 21282545
references.citation: Bone Marrow Transplant. 2008 May;41(9):765-70
references.pmid: 18195684
references.citation: Blood. 2012 Jun 28;119(26):6379-81
references.pmid: 22611160
references.citation: J Clin Oncol. 2012 Jun 20;30(18):2183-9
references.pmid: 22454421